Update from the Washington State Institute for Public Policy on the Initiative 502 Evaluations

WASHINGTON STATE INSTITUTE FOR PUBLIC POLICY

Eva Westley, MPH Amani Rashid, PhD House Regulated Substances & Gaming Committee: Work Session

March 9, 2023

WASHINGTON STATE INSTITUTE FOR PUBLIC POLICY

WSIPP Board of Directors

Senator Chris Gildon, Co-Chair

Senator Andy Billig

Senator Marko Liias

Senator Mark Schoesler

Kim Johnson, Senate Staff Dir.

David Schumacher, OFM

Sarah Norris Hall, UW

John Carmichael, TESC

Representative Larry Springer, Co-Chair

Representative Cyndy Jacobsen

Representative Timm Ormsby

Vacancy (Representative)

Jill Reinmuth, House Staff Dir.

Nick Streuli, Gov. Policy Dir.

Kate Destler, WWU

Bidisha Mandal, WSU

WSIPP'S WORK


Our role is to provide **rigorous, non-partisan research** on topics of legislative interest.

We specialize in **quantitative research**, including outcome evaluations, economic analyses, and evidence reviews.

WSIPP's research projects are initiated and funded through:

- Legislative assignments
- Approval by WSIPP's Board of Directors. The work must be:
 - ✓ Of importance to the state
 - ✓ Consistent with WSIPP's non-partisan mission

WSIPP'S CANNABIS-RELATED STUDIES



Today's focus

- 2) Board-approved contract: Employment and Wage Earnings in Licensed Marijuana Businesses (2017)
- 3) 2018 supplemental operating budget
 - Suppressing Illicit Cannabis Markets After State Marijuana Legalization (2019)
 - ✓ Measuring Youth Cannabis Use in Washington State (2019)
 - Updated Inventory of Programs for the Prevention and Treatment of Youth Cannabis Use (2019)

WSIPP'S INITIATIVE 502 (I-502) ASSIGNMENT

RCW 69.50.550

WSIPP shall conduct cost-benefit evaluations for the implementation of [this act]...The evaluations shall include, but *not necessarily be limited to*:

- Public health and health care,
- Public safety,
- Substance use,
- Criminal justice,
- Economic impacts, and
- Administrative costs and revenues


abbreviated assignment language


I-502 BENEFIT COST ANALYSIS (BCA)


• How did I-502 change outcomes?


- Several outcomes to consider
- Different components to I-502
 - » Legalized adult possession
 - » Established legal retail market
 - » Mandated prevention and education















I-520 EVALUATION: PRELIMINARY FINDINGS (2017)

National data

- I-502 *did not relate to* changes in cannabis abuse treatment
 - Compared to other states
 - Study period: 2000-2014

WA State data

- Higher county cannabis sales *related to* higher reported adult cannabis use
 - Study period: 2011-2015
- County cannabis sales *did not relate to* changes in
 - reported youth cannabis use (study period: 2002-2016)
 - drug-related convictions (study period: 2005-2016)



1. Review of Cannabis Policy, Revenues, and Expenditures (Forthcoming June 2023)

- Relevant policy
- Past-decade revenues and expenditures

2. Outcome Evaluations

(Forthcoming September 2023)

- How cannabis legalization/retail relates to:
 - Reported substance use
 - Related diagnoses and health care use
 - Traffic safety
 - Criminal justice outcomes


National data

- Reported substance use
 - Examines how reported cannabis use and other substance use changed after I-502 (12/12) and commercial sales (07/14)
 - Compared to other states
 - Outcomes include reported use of:
 - » Cannabis
 - » Alcohol
 - » Cigarettes
 - » Other drugs

WA State data

• Impact of local access to licensed cannabis retailers in WA.

Nonmedical Cannabis Retail Licensee Locations, Counties 2019



Reported cannabis use

- Population of surveyed adults ages 21+
- Outcomes include reported:
 - » Any/past-month/heavy cannabis use

Substance Use Disorder and Health Care

- Population of Medicaid enrollees ages 12+
- Outcomes:
 - » Cannabis, alcohol, opioid use disorder diagnoses
 - » Psychotic disorder, mania/bipolar, depression diagnoses
 - » Substance use & mental health treatment
 - » Antipsychotic, antianxiety, antidepression prescriptions

Traffic Fatalities

- Population of all drivers in fatal crash
- Outcomes include drivers testing positive for:
 - » Cannabis (THC > 5ng/mL)
 - » Alcohol, other drugs, poly-drug use

Criminal Justice

- Population of persons with charges filed
- Outcomes include cannabis/substance related:
 - » Charges
 - » Convictions (including DUI)
 - » Sentencing

1. Review of Cannabis Policy, Revenues, and Expenditures (June 2023)

2. Outcome Evaluations (September 2023)

> Reports will be available on our website at wsipp.wa.gov/Publications

Reports are also circulated to relevant committees, committee staff, and our Board of Directors.

THANK YOU!

Questions?

Amani Rashid, PhD

I-502 Evaluation Project Lead, Senior Research Associate <u>amani.rashid@wsipp.wa.gov</u>

Eva Westley, MPH

Associate Director for Research

eva.westley@wsipp.wa.gov

APPENDIX

ADDITIONAL RESOURCES WSIPP'S CANNABIS-RELATED RESEARCH

Website: <u>www.wsipp.wa.gov</u>

I-502 Evaluation Reports:

<u>I-502 Evaluation Plan and Preliminary Report on Implementation</u> (2015)

I-502 Evaluation and Benefit-Cost Analysis: Second Required Report (2017)

Other Cannabis-Related Reports: Employment and Wage Earnings in Licensed Marijuana Businesses (2017)

Suppressing Illicit Cannabis Markets After State Marijuana Legalization (2019)

Measuring Youth Cannabis Use in Washington State (2019)

<u>Updated Inventory of Programs for the Prevention and Treatment of Youth</u> <u>Cannabis Use</u> (2019)